Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01936844 · ClinicalTrials.gov registry record · Phase 2
Interleukin (IL)-1 Blockade in Acute Heart Failure (Anakinra ADHF)
A Phase 2 study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT01936844 is a Phase 2 study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 30 participants.
The verdict
NCT01936844, a Phase 2 study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
Anakinra ADHF is a double-blind randomized clinical trial of anakinra, recombinant human interleukin-1 receptor blocker, or placebo in patients with acute decompensated heart failure with the aim to quench the acute inflammatory response, as measured by the area-under-the-curve for C reactive protein over 14 days.
Interventions
- DRUG Placebo
- DRUG Anakinra (high dose)
- DRUG Anakinra (standard dose)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2014-02 |
| Est. Completion | 2015-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01936844
The ClinicalTrials.gov registry entry for NCT01936844 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01936844 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01936844 about?
NCT01936844 is a clinical study titled "Interleukin (IL)-1 Blockade in Acute Heart Failure (Anakinra ADHF)". Anakinra ADHF is a double-blind randomized clinical trial of anakinra, recombinant human interleukin-1 receptor blocker, or placebo in patients with acute decompensated heart failure with the aim to quench the acute inflammatory response, as measured by the area-under-the-curve for C reactive protei...
What is the current status of trial NCT01936844?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2014-02. Estimated completion is 2015-05.
What interventions are being tested in trial NCT01936844?
The interventions under investigation include: Placebo (DRUG), Anakinra (high dose) (DRUG), Anakinra (standard dose) (DRUG).
Who is sponsoring clinical trial NCT01936844?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.